Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose

被引:46
作者
Landry, P [1 ]
Tremblay, S [1 ]
Darioli, R [1 ]
Genton, B [1 ]
机构
[1] Univ Lausanne, Med Policlin, Travel Clin, CH-1005 Lausanne, Switzerland
关键词
hepatitis A; vaccine; booster; traveler;
D O I
10.1016/S0264-410X(00)00188-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
We investigated what happens with the immune response when people come back for their booster dose of inactivated hepatitis A vaccine later than the recommended time of 6-12 months after the primary dose. We recruited a group of 124 travellers who received either the primary doses of Havrix 720(TM) (two doses) or of Havrix 1440(TM) (one dose) greater than or equal to 24 months before study entry. They received a booster dose of Havrix 1440(TM) and blood was drawn 1 month later. As a control group, we recruited a group of 125 travellers who followed a recommended schedule with a primary dose at month 0 and a booster dose at months 6-12. For both study groups, the GMTs increased dramatically and similarly upon the booster immunisation. Although significantly more late travellers (32%) had lost detectable antibodies than controls (11%) before administration of the booster dose, all these subjects showed an anamnestic response to the booster dose. Delaying the booster dose up to 66 months after primary vaccination did not seem to influence the immunogenicity of the booster dose. However, the recommended 6-12-month interval remains if detectable antibody titers are to be warranted constantly. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:399 / 402
页数:4
相关论文
共 14 条
[1]
ANDRE FE, 1997, VIRAL HEPATITIS DIS, P624
[2]
Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other ''travellers'' vaccines with the immune response [J].
Bienzle, U ;
Bock, HL ;
Kruppenbacher, JP ;
Hofmann, F ;
Vogel, GE ;
Clemens, R .
VACCINE, 1996, 14 (06) :501-505
[3]
Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines [J].
Bovier, PA ;
Althaus, B ;
Glueck, R ;
Chippaux, A ;
Loutan, L .
JOURNAL OF TRAVEL MEDICINE, 1999, 6 (04) :228-233
[4]
CEDERNA JB, 1996, INT S VIR HEP LIV DI
[5]
EFFECT OF VIRUS-STRAIN AND ANTIGEN DOSE ON IMMUNOGENICITY AND REACTOGENICITY OF AN INACTIVATED HEPATITIS-A VACCINE [J].
GOUBAU, P ;
VANGERVEN, V ;
SAFARY, A ;
DELEM, A ;
KNOPS, J ;
DHONDT, E ;
ANDRE, FE ;
DESMYTER, J .
VACCINE, 1992, 10 :S114-S118
[6]
Iwarson S, 1998, J Travel Med, V5, P80, DOI 10.1111/j.1708-8305.1998.tb00468.x
[7]
IMMUNOGENICITY OF AN INACTIVATED HEPATITIS-A VACCINE IN ALASKA NATIVE CHILDREN AND NATIVE AND NONNATIVE ADULTS [J].
MCMAHON, BJ ;
WILLIAMS, J ;
BULKOW, L ;
SNOWBALL, M ;
WAINWRIGHT, R ;
KENNEDY, M ;
KRAUSE, D .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :676-679
[8]
INACTIVATED HEPATITIS-A VACCINE - A SAFETY AND IMMUNOGENICITY STUDY IN HEALTH-PROFESSIONALS [J].
SANDMAN, L ;
DAVIDSON, M ;
KRUGMAN, S .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 :S50-S52
[9]
SCHMIDTKE P, 1997, 35 ICAAC
[10]
INACTIVATED HEPATITIS-A VACCINE - REACTOGENICITY, IMMUNOGENICITY, AND LONG-TERM ANTIBODY PERSISTENCE [J].
VANDAMME, P ;
THOELEN, S ;
CRAMM, M ;
DEGROOTE, K ;
SAFARY, A ;
MEHEUS, A .
JOURNAL OF MEDICAL VIROLOGY, 1994, 44 (04) :446-451